Literature DB >> 17260018

Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.

Y Kang1, J A Hong, G A Chen, D M Nguyen, D S Schrump.   

Abstract

Previously, we reported that the paralogous zinc-finger proteins--CTCF and brother of the regulator of imprinted sites (BORIS), directly contribute to transcriptional regulation of NY-ESO-1 in lung cancer cells. To further examine mechanisms that mediate expression of this cancer-testis gene, we performed software-guided analysis of the NY-ESO-1 promoter region, which revealed several potential Sp1-binding motifs. Sequential 5-aza-2'deoxycytidine/depsipeptide FK228 treatment markedly induced BORIS expression and enhanced nuclear translocation of Sp1 in lung cancer cells. Transient transfection assays using promoter-reporter constructs, as well as gel-shift and chromatin immunoprecipitation experiments revealed that NY-ESO-1 promoter activity coincided with occupancy of the proximal Sp1-binding site in lung cancer cells. Mutations within the Sp1 recognition sequence specifically eliminated binding of Sp1 to this motif in vitro, and markedly diminished NY-ESO-1 promoter activity in vivo. siRNA-mediated inhibition of Sp1 expression decreased NY-ESO-1 promoter activity, whereas knock down of CTCF expression augmented NY-ESO-1 transcription in lung cancer cells. Co-immunoprecipitation experiments indicated that Sp1 physically interacts with BORIS but not with CTCF in vivo. Collectively, these findings suggest that BORIS recruits Sp1 to mediate de-repression of NY-ESO-1 during pulmonary carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260018     DOI: 10.1038/sj.onc.1210218

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

Review 1.  Targeting the epigenome in malignant pleural mesothelioma.

Authors:  Kaitlin C McLoughlin; Andrew S Kaufman; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  A genome-wide gene-environment interaction analysis for tobacco smoke and lung cancer susceptibility.

Authors:  Ruyang Zhang; Minjie Chu; Yang Zhao; Chen Wu; Huan Guo; Yongyong Shi; Juncheng Dai; Yongyue Wei; Guangfu Jin; Hongxia Ma; Jing Dong; Honggang Yi; Jianling Bai; Jianhang Gong; Chongqi Sun; Meng Zhu; Tangchun Wu; Zhibin Hu; Dongxin Lin; Hongbing Shen; Feng Chen
Journal:  Carcinogenesis       Date:  2014-03-22       Impact factor: 4.944

3.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.

Authors:  Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz
Journal:  Cell Death Discov       Date:  2020-01-02

4.  Identification and functional characterization of glioma-specific promoters and their application in suicide gene therapy.

Authors:  Toshio Yawata; Yusuke Maeda; Makiko Okiku; Eri Ishida; Kazuhiro Ikenaka; Keiji Shimizu
Journal:  J Neurooncol       Date:  2011-02-24       Impact factor: 4.130

Review 5.  Chromatin insulators: a role in nuclear organization and gene expression.

Authors:  Jingping Yang; Victor G Corces
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

6.  BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.

Authors:  Sheetal Bhan; Sandeep S Negi; Chunbo Shao; Chad A Glazer; Alice Chuang; Daria A Gaykalova; Wenyue Sun; David Sidransky; Patrick K Ha; Joseph A Califano
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

7.  Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells.

Authors:  Maria Buoncervello; Paola Borghi; Giulia Romagnoli; Francesca Spadaro; Filippo Belardelli; Elena Toschi; Lucia Gabriele
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

8.  Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.

Authors:  Chad A Glazer; Ian M Smith; Michael F Ochs; Shahnaz Begum; William Westra; Steven S Chang; Wenyue Sun; Sheetal Bhan; Zubair Khan; Steven Ahrendt; Joseph A Califano
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

9.  HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression.

Authors:  Pierre-François Cartron; Christophe Blanquart; Eric Hervouet; Marc Gregoire; François M Vallette
Journal:  Mol Oncol       Date:  2012-12-21       Impact factor: 6.603

10.  Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.

Authors:  Jimmie Colon; Md Riyaz Basha; Rafael Madero-Visbal; Santhi Konduri; Cheryl H Baker; Luis J Herrera; Stephen Safe; David Sheikh-Hamad; Ala Abudayyeh; Beatrice Alvarado; Maen Abdelrahim
Journal:  Invest New Drugs       Date:  2009-10-23       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.